

Hidetaka Kamimura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6401488/publications.pdf>

Version: 2024-02-01

12
papers

201
citations

1307594

7
h-index

1199594

12
g-index

12
all docs

12
docs citations

12
times ranked

115
citing authors

#	ARTICLE	IF	CITATIONS
1	An improved TK-NOG mouse as a novel platform for humanized liver that overcomes limitations in both male and female animals. <i>Drug Metabolism and Pharmacokinetics</i> , 2022, 42, 100410.	2.2	19
2	Human total clearance values and volumes of distribution of typical human cytochrome P450 2C9/19 substrates predicted by single-species allometric scaling using pharmacokinetic data sets from common marmosets genotyped for P450 2C19. <i>Xenobiotica</i> , 2021, 51, 479-493.	1.1	3
3	Empirical and theoretical approaches for the prediction of human hepatic clearance using chimeric mice with humanised liver: the use of physiologically based scaling, a novel solution for potential overprediction due to coexisting mouse metabolism. <i>Xenobiotica</i> , 2021, 51, 983-994.	1.1	1
4	A novel C _{ss} -MRT _{po} approach to simulate oral plasma concentration–time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite in humans using chimeric mice with humanized livers. <i>Xenobiotica</i> , 2020, 50, 761-768.	1.1	1
5	Human plasma concentration-time profiles of troglitazone and troglitazone sulfate simulated by in vivo experiments with chimeric mice with humanized livers and semi-physiological pharmacokinetic modeling. <i>Drug Metabolism and Pharmacokinetics</i> , 2020, 35, 505-514.	2.2	3
6	Predicted values for human total clearance of a variety of typical compounds with differently humanized-liver mouse plasma data. <i>Drug Metabolism and Pharmacokinetics</i> , 2020, 35, 389-396.	2.2	4
7	Simulation of human plasma concentration–time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite using humanized chimeric mice and semi-physiological pharmacokinetic modeling. <i>Xenobiotica</i> , 2017, 47, 382-393.	1.1	26
8	Assessment of chimeric mice with humanized livers in new drug development: generation of pharmacokinetics, metabolism and toxicity data for selecting the final candidate compound. <i>Xenobiotica</i> , 2016, 46, 557-569.	1.1	16
9	Formation of the Accumulative Human Metabolite and Human-Specific Glutathione Conjugate of Diclofenac in TK-NOG Chimeric Mice with Humanized Livers. <i>Drug Metabolism and Disposition</i> , 2015, 43, 309-316.	3.3	31
10	Development of Murine <i>Cyp3a</i> Knockout Chimeric Mice with Humanized Liver. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1208-1217.	3.3	26
11	Assessment of Chimeric Mice with Humanized Liver as a Tool for Predicting Circulating Human Metabolites. <i>Drug Metabolism and Pharmacokinetics</i> , 2010, 25, 223-235.	2.2	52
12	THE CANINE CYP1A2 DEFICIENCY POLYMORPHISM DRAMATICALLY AFFECTS THE PHARMACOKINETICS OF 4-CYCLOHEXYL-1-ETHYL-7-METHYLPYRIDO[2,3-D]-PYRIMIDINE-2-(1H)-ONE (YM-64227), A PHOSPHODIESTERASE TYPE 4 INHIBITOR. <i>Drug Metabolism and Disposition</i> , 2006, 34, 800-806.	3.3	19